



Vaccine Research against Significant Viral Diseases of Poultry

Guest Editor:

Dr. Kiril Dimitrov

Texas A&M Veterinary Medical
Diagnostic Laboratory, Texas A
and M University System disabled,
College Station, TX 77843, USA

Deadline for manuscript
submissions:

closed (30 June 2021)

Message from the Guest Editor

Dear Colleagues,

The global poultry industry accounts for the production of over 115 million metric tons of meat and eggs. By 2030, the world is anticipated to need food for more than eight billion people. Due to the growing world population and increased protein consumption demand, it is projected that poultry production will increase by 25% during the next decade. In many developing countries, poultry is the main source of protein and income in rural areas. Some viral poultry diseases such as (but not limited to) avian influenza, infectious bronchitis, infectious laryngotracheitis, Marek's disease, Newcastle disease, and reoviral arthritis are of great economic and social importance. Such diseases are controlled through vaccination and strict biosecurity, and in many countries, some are contained using stamping out. However, due to the continuing evolution of some of these viruses and emergence of new virulent variants, vaccination has not always been fully effective. For others, such as infectious laryngotracheitis and reoviral infections, vaccine development is challenging.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)